ClinicalTrials.gg
CompletedNCT01766050Updated Jun 27, 2014Results posted

Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers

A Phase 4 interventional study of Caffeine and Losartan in Transplant Rejection, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-27.

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to determine the effects of belatacept on the pharmacokinetics of caffeine, losartan, omeprazole, dextromethorphan and midazolam

02

Conditions studied

  • Transplant Rejection
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 30 kg/m2
  • Men and women ages 18 to 45

Exclusion criteria

Exclusion Criteria:

  • Active tuberculosis
  • Any recent infection requiring antibiotic treatment within 4 weeks of dosing
  • Positive urine screen for drugs of abuse
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Arm: Inje Cocktail + Belatacept

    Inje Cocktail consisting of (200 mg Caffeine, 50 mg losartan tablet, 40 mg Omeprazole capsule, 30 mg Dextromethorphan capsule and 5 mg Midazolam oral syrup) administered on Days 1, 4, 7 and 11 Belatacept 10 mg/kg Intravenous (IV) solution, administered on Day 4

    Drug: Caffeine · Drug: Losartan · Drug: Omeprazole · Drug: Dextromethorphan · Drug: Midazolam · Biological: Belatacept

Interventions

06

What researchers measure

Primary outcomes

  1. Adjusted Geometric Mean Maximum Drug Concentration (Cmax) of Midazolam With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population

    Samples for the assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for midazolam with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Cmax measured in nanograms per milliliter (ng/mL). Inje cocktail components (Midazolam) measured using High Performance Liquid Chromatography (HPLC) with Tandem Mass Spectrometry (MS/MS) Detection.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  2. Adjusted Geometric Mean Area Under the Concentration Time Curve (AUC) From Zero to Last Concentration (0-T) and AUC Extrapolated to Infinity (INF) of Midazolam With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population

    AUC(0-T): area under the plasma concentration-time curve from zero to the last time of the last quantifiable concentration and AUC (INF): AUC from time zero extrapolated to infinite time were measured in ng\*h/mL. Samples for the assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for midazolam with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Midazolam measured using HPLC with MS/MS Detection.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7and 11

  3. Adjusted Geometric Mean Cmax of Losartan With and Without the Coadministration of Belatacept - PK Evaluable Population

    Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for losartan with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Inje cocktail components (losartan) measured using HPLC with MS/MS Detection.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  4. Adjusted Geometric Mean AUC (0-T) and AUC (INF) of Losartan With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population

    AUC (0-T): area under the concentration curve from time 0 to the time of the last quantifiable concentration and AUC (INF) extrapolated to infinity were measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for losartan with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Inje cocktail components (losartan) measured using HPLC with MS/MS Detection.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  5. Adjusted Geometric Mean Cmax of Omeprazole With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population

    Cmax: Maximum observed plasma concentration was measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for omeprazole with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Inje cocktail components (omeprazole) measured using HPLC with MS/MS Detection.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  6. Adjusted Geometric Mean AUC (0-T) and AUC (INF) of Omeprazole With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population

    AUC(0-T): Area under the plasma concentration-time curve from time zero zero to the time of the last quantifiable concentration and AUC (INF): AUC extrapolated to infinity were measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for omeprazole with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Inje cocktail components (omeprazole) measured using HPLC with MS/MS Detection.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  7. Adjusted Geometric Mean Cmax of Dextromethorphan With and Without the Coadministration of Belatacept - PK Evaluable Population

    Cmax was measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for dextromethorphan with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. The poor metabolizer of CYP2D6 was excluded from the statistical analysis. Inje cocktail components (dextromethorphan) measured using HPLC with MS/MS Detection.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  8. Adjusted Geometric Mean AUC (0-T) and AUC (INF) of Dextromethorphan With and Without the Coadministration of Belatacept - PK Evaluable Population

    AUC(0-T): area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration and AUC (INF): AUC extrapolated to infinity, were measured as ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for dextromethorphan with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. The poor metabolizer of CYP2D6 was excluded from the statistical analysis. Inje cocktail components (dextromethorphan) measured using HPLC with MS/MS Detection.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  9. Adjusted Geometric Mean Cmax of Caffeine With and Without the Coadministration of Belatacept - PK Evaluable Population

    Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection. Cmax was measured in ng/mL.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  10. Adjusted Geometric Mean AUC (0-T) and AUC (INF) of Caffeine With and Without the Coadministration of Belatacept - PK Evaluable Population

    Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection. AUC (0-T) and AUC (INF) were measured as ng\*h/mL.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

Secondary outcomes

  1. Time of Maximum Observed Plasma Concentration (Tmax) of the Inje Cocktail Components (Midazolam, Losartan, Omeprazole, Dextromethorphan, and Caffeine) With and Without Coadministration of Belatacept - PK Evaluable Population

    Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of dextromethorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection. Tmax was measured in hours (h).

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  2. Plasma Half-Life (T-HALF) of the Inje Cocktail Components (Midazolam, Losartan, Omeprazole, Dextromethorphan, and Caffeine) With and Without Coadministration of Belatacept - PK Evaluable Population

    Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of dextromethorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection. T-HALF was measured in hours (h).

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  3. Apparent Total Body Clearance (CLT/F) of the Inje Cocktail Components (Midazolam, Losartan, Omeprazole, Dextromethorphan and Caffeine) With and Without Coadministration of Belatacept - PK Evaluable Population

    Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of dextromethorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection. CLT/F was measured as liters/hour (L/h)

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  4. Cmax of Inje Cocktail Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without Coadministration of Belatacept - PK Evaluable Population

    Samples for assessment of plasma concentrations of Inje cocktail component metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail component metabolites were each measured using HPLC with MS/MS detection. Cmax was measured in ng/mL.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  5. AUC(0-T) of Inje Cocktail Component Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without Coadministration of Belatacept - PK Evaluable Population

    Area under the plasma concentration-time curve from zero to the last time of the last quantifiable concentration \[AUC(0-T)\] was measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  6. AUC(INF) of Inje Cocktail Component Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without Coadministration of Belatacept - PK Evaluable Population

    Area under the plasma concentration-time curve from time zero extrapolated to infinite time \[AUC(INF)\] was measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  7. Tmax of Inje Cocktail Component Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without the Coadministration of Belatacept - PK Evaluable Population

    Samples for assessment of plasma concentrations of Inje cocktail components metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection. Time of maximum observed plasma concentration (Tmax) was measured in hours (h).

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  8. T-HALF of Inje Cocktail Component Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without the Coadministration of Belatacept - PK Evaluable Population

    Plasma half-life (T-HALF) was measured in hours (h). Samples for assessment of plasma concentrations of Inje cocktail components metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  9. Ratio of Paraxanthine AUC(0-T) to Caffeine AUC(0-T) and Paraxanthine AUC (INF) to Caffeine AUC (INF), Corrected for Molecular Weight [MR_AUC(0-T) and MR_AUC (INF)] With and Without Coadministration of Belatacept - PK Evaluable Population

    Metabolite (paraxanthine) to parent (caffeine) ratio was corrected for molecular weight. AUC (0-T) and AUC (INF) measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  10. Ratio of Paraxanthine (Cmax) to Caffeine (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population

    Metabolite (paraxanthine) to parent (caffeine) ratio was corrected for molecular weight. Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components and their metabolites were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  11. Ratio of E-3174 AUC(0-T) to Losartan AUC(0-T) and E3174 AUC (INF) to Losartan AUC (INF) Corrected for Molecular Weight [MR_AUC(0-T), MR_AUC(INF)] With and Without Coadministration of Belatacept - PK Evaluable Population

    Metabolite (E-3174) to parent (losartan) ratio was corrected for molecular weight. AUC (0-T) and AUC (INF) measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  12. Ratio of E-3174 (Cmax) to Losartan (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population

    Metabolite (E-3174) to parent (losartan) ratio was corrected for molecular weight. Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  13. Ratio of 5-Hydroxyomeprazole AUC(0-T) to Omeprazole AUC(0-T) and 5-Hydroxyomeprazole AUC(INF) to Omeprazole AUC(INF) , Corrected for Molecular Weight [MR_AUC(0-T), MR_AUC(INF)] With and Without Coadministration of Belatacept - PK Evaluable Population

    Metabolite (5-Hydroxyomeprazole) to parent (omeprazole) ratio was corrected for molecular weight. AUC (0-T) and AUC (INF) measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  14. Ratio of 5-Hydroxyomeprazole (Cmax) to Omeprazole (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population

    Metabolite (5-hydroxyomeprazole) to parent (omeprazole) ratio was corrected for molecular weight. Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  15. Ratio of 5-Dextrorphan AUC(0-T) to Dextromethorphan AUC(0-T) and 5-Dextrorphan AUC(INF) to Dextromethorphan AUC(INF), Corrected for Molecular Weight [MR_AUC(0-T), MR_AUC (INF)] With and Without Coadministration of Belatacept - PK Evaluable Population

    Metabolite (5-dextrorphan ) to parent (dextromethorphan) ratio was corrected for molecular weight. AUC (0-T) and AUC (INF) measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  16. Ratio of 5-Dextrorphan (Cmax) to Dextromethorphan (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population

    Metabolite (5-dextrorphan) to parent (dextromethorphan) ratio was corrected for molecular weight. Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  17. Ratio of 1'-Hydroxy-Midazolam AUC(0-T) to Midazolam AUC(0-T) and 1'-Hydroxy-Midazolam AUC(INF) to Midazolam AUC(INF), Corrected for Molecular Weight [MR_AUC(0-T), MR_AUC (INF)] With and Without Coadministration of Belatacept - PK Evaluable Population

    Metabolite (1'-hydroxy-midazolam) to parent (midazolam) ratio was corrected for molecular weight. AUC (0-T) and AUC (INF) measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  18. Ratio of 1'-Hydroxy-Midazolam (Cmax) to Midazolam (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population

    Metabolite (1'-hydroxy-midazolam) to parent (midazolam) ratio was corrected for molecular weight. Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.

    Time frame: Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11

  19. Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and AEs Leading to Discontinuation - All Treated Participants

    Adverse events were coded according to the Medical Dictionary for Regulatory Activities (MedDRA), version 15.1. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Events captured from Day 1 (pre-dose) to last day prior to discharge (Day 46 ±2). In the total group, a participant with an AE is only counted once (ie, data reflected in Days 1, 4, 7, and 11 below could be the same participant with an AE on multiple days of the study).

    Time frame: Day 1 to Day of discharge (Day 46±2)

  20. Number of Participants With Marked Serum Chemistry Laboratory Abnormalities - All Treated Participants

    Samples for laboratory tests were obtained at Screening visit, Day -1 or prior to dosing on Day 1, Days 3, 6, 10, 46, and at early termination, after 10 hours fasting. Upper limits of normal (ULN); Lower limits of normal (LLN); Pre-therapy (Rx); micromoles per liter (µmol/L); millimoles per liter (mmol/L); grams per liter (g/L); Units per liter (U/L); Aspartate Aminotransferase (AST); Blood Urea Nitrogen (BUN) Total Bilirubin: \>1.1\*ULN if Pre-Rx\<= ULN or Pre-Rx is missing, or \>1.2\*Pre-Rx if Pre-Rx \>ULN. AST: \>1.25\*Pre-Rx if Pre-Rx \>ULN or 1.25\*ULN if Pre-Rx \<= ULN or Pre-Rx is missing. BUN: \>1.1\*ULN if Pre-Rx\<= ULN or Pre-Rx is missing, or \>1.2\*Pre-Rx if Pre-Rx \>ULN. Phosphorus: \<0.85\*LLN if Pre-RX \>= LLN or is missing or if Pre-Rx \< LLN. total Protein: \<0.9\*LLN if Pre-Rx\>= LLN or is missing or Pre-Rx \> LLN. Creatine Kinase: \>1.5\*Pre-Rx if Pre-Rx \> ULN or is missing or Pre-Rx is \<= ULN. Lactate Dehydrogenase: \>1.25\*ULN if Pre-Rx \<= ULN or missing, \>1.5\*Pre-Rx if Pre-Rx \> ULN.

    Time frame: Day -1 to Day 46 ±2 days or at early termination

  21. Number of Participants With Marked Hematology and Urinalysis Laboratory Abnormalities - All Treated Participants

    Samples for laboratory tests were obtained at Screening visit, Day -1 or prior to dosing on Day 1, Days 3, 6, 10, 46 ±2, and at early termination, after 10 hours fasting. Leukocytes: \*10\^9 cells per liter (c/L) \< 0.85\*Pre-Rx if Pre-Rx \< LLN or \<0.9\*LLN if LLN \<= Pre-Rx or Pre-Rx is missing. Neutrophils (absolute): \*10\^12 c/L \< 0.85\* Pre-Rx if Pre-Rx \< 1.5, \<1.5 if Pre-Rx \>= 1.5, \< 1.5 if Pre-Rx missing. Urine blood from dipstick: \>=2 if Pre-Rx \<1 or was missing or if Pre-Rx \>=1. Urinary microscopic white blood cells (WBC) and red blood cells (RBC) \>= 2 if Pre-Rx \<2 or if Pre-Rx was missing or \>=4 if Pre-Rx \>=2.

    Time frame: Day -1 to Day 46 ±2 days or at early termination

  22. Number of Participants With Out-of-Range Electrocardiogram Intervals - All Treated Participants

    Participants had 12-Lead electrocardiograms (ECGs) performed at Screening Visit, Day 1 prior to dosing, Day 46 ±2, and at early termination. Definition of out-of-range: PR Interval \>210 milliseconds (msec); QRS \> 120 msec, QT \> 500 msec or \> 30 msec change from baseline (Day 1); QT with Fridericia correction (QTcF) \> 450 msec or change from baseline of \> 30 msec to \<= 60 msec or change from baseline \> 60 msec.

    Time frame: Day 1 to Day 46 ±2 days or at early termination

  23. Mean Change From Baseline in Sitting Systolic and Diastolic Blood Pressure - All Treated Participants

    Systolic and Diastolic blood pressures were taken after the participant had been sitting quietly for at least 5 minutes and the pressures were measured in millimeters of mercury (mm Hg). Pressures were obtained at screening visit, Day -1, and at 0 hour (pre-dose), 0.5 hour (post dose), and 2 hours (post dose) on Days 1, 4, 7, 11. Baseline was defined as last non-missing result with a collection date-time less than the date-time of the first active dose of study drug.

    Time frame: Baseline and 0.5 and 2.0 hours Post Dose on Days 1, 4, 7, and 11

  24. Mean Change From Baseline in Sitting Heart Rate - All Treated Participants

    Heart Rate was taken after the participant had been sitting quietly for at least 5 minutes and the heart rate was measured in beats per minute (bpm). Heart Rates were obtained at screening visit, Day -1, and at 0 hour (pre-dose), 0.5 hour (post dose), and 2 hours (post dose) on Days 1, 4, 7, 11. Baseline was defined as last non-missing result with a collection date-time less than the date-time of the first active dose of study drug.

    Time frame: Baseline and 0.5 and 2.0 hours Post Dose on Days 1, 4, 7, and 11

  25. Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Study Discharge (Day 46±2 Days)

    Systolic and Diastolic blood pressures were taken after the participant had been sitting quietly for at least 5 minutes and the pressures were measured in millimeters of mercury (mm Hg). Systolic and Diastolic blood pressures were taken on Day 46 (day of discharge from the study). Baseline was defined as last non-missing result with a collection date-time less than the date-time of the first active dose of study drug.

    Time frame: Baseline and Day 46 ±2 days

  26. Mean Change From Baseline in Heart Rate at Study Discharge (Day 46±2 Days)

    Heart Rate was taken after the participant had been sitting quietly for at least 5 minutes and was measured in beats per minute (bpm). Hear rate was taken on Day 46 (day of discharge) during the follow up period. Baseline was defined as last non-missing result with a collection date-time less than the date-time of the first active dose of study drug.

    Time frame: Baseline and Day 46 ±2 days

07

Results

Posted Jun 27, 2014

Participant flow

Study initiated January 2013 and completed April 2013. Participants (healthy volunteers) checked into a clinical pharmacology unit (CPU) on Day -1 for screening.

Participant flow — Overall Study
MilestoneInje Cocktail Alone and Inje Cocktail Plus Belatacept
Started22
Completed18
Not completed4
Withdrew: Adverse event1
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryAdjusted Geometric Mean Maximum Drug Concentration (Cmax) of Midazolam With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population

Samples for the assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for midazolam with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Cmax measured in nanograms per milliliter (ng/mL). Inje cocktail components (Midazolam) measured using High Performance Liquid Chromatography (HPLC) with Tandem Mass Spectrometry (MS/MS) Detection.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Geometric mean · ng/mL
Adjusted Geometric Mean Maximum Drug Concentration (Cmax) of Midazolam With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population
ng/mLDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
Adjusted Geometric Mean Maximum Drug Concentration (Cmax) of Midazolam With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population24.376 ± 4224.152 (20.632 to 28.271)22.211 (19.131 to 25.787)24.220 (20.835 to 28.154)
Statistical analysis
  • Day 1 Inje Cocktail vs Day 4 Inje Cocktail Plus Belatacept · Adjusted geometric mean ratio: 0.991 · 90% CI 0.898 to 1.093
  • Day 1 Inje Cocktail vs Day 7 Inje Cocktail · Adjusted geometric mean ratio: 0.911 · 90% CI 0.830 to 1.000
  • Day 1 Inje Cocktail vs Day 11 Inje Cocktail · Adjusted geometric mean ratio: 0.994 · 90% CI 0.885 to 1.116
SecondaryTime of Maximum Observed Plasma Concentration (Tmax) of the Inje Cocktail Components (Midazolam, Losartan, Omeprazole, Dextromethorphan, and Caffeine) With and Without Coadministration of Belatacept - PK Evaluable Population

Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of dextromethorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection. Tmax was measured in hours (h).

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Median · h
Time of Maximum Observed Plasma Concentration (Tmax) of the Inje Cocktail Components (Midazolam, Losartan, Omeprazole, Dextromethorphan, and Caffeine) With and Without Coadministration of Belatacept - PK Evaluable Population
hDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
Midazolam (N=22,21,21,20)0.50 (0.50 to 1.50)0.50 (0.50 to 1.50)0.50 (0.50 to 1.50)1.0 (0.50 to 1.03)
Losartan (N= 22, 21, 21, 20)1.52 (0.50 to 3.00)2.00 (0.50 to 4.00)1.50 (0.50 to 3.00)1.50 (0.50 to 3.00)
Omeprazole (N=22,21,21,20)2.00 (1.50 to 4.00)3.00 (1.00 to 8.05)3.00 (1.00 to 5.00)3.00 (1.00 to 12.00)
Dextromethorphan (N=21, 19, 19, 19)3.00 (1.00 to 6.00)3.00 (1.50 to 6.00)3.00 (1.50 to 5.15)3.00 (1.00 to 6.00)
Caffeine (N= 22,21,21,18)1.00 (0.50 to 2.00)1.00 (0.50 to 3.00)1.50 (0.50 to 4.00)1.50 (0.50 to 2.00)
SecondaryPlasma Half-Life (T-HALF) of the Inje Cocktail Components (Midazolam, Losartan, Omeprazole, Dextromethorphan, and Caffeine) With and Without Coadministration of Belatacept - PK Evaluable Population

Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of dextromethorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection. T-HALF was measured in hours (h).

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Mean · h
Plasma Half-Life (T-HALF) of the Inje Cocktail Components (Midazolam, Losartan, Omeprazole, Dextromethorphan, and Caffeine) With and Without Coadministration of Belatacept - PK Evaluable Population
hDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
Midazolam (N=22, 21, 21, 20)4.01 ± 1.864.43 ± 1.894.27 ± 1.884.05 ± 1.61
Losartan (N=22, 21, 21, 20)2.96 ± 1.292.56 ± 1.313.30 ± 1.492.87 ± 1.52
Omeprazole (N= 22, 19, 21, 18)1.19 ± 0.4971.39 ± 0.5691.28 ± 0.4701.36 ± 0.907
Dextromethorphan (N=18, 17, 18, 15)6.76 ± 2.096.98 ± 2.676.33 ± 1.696.70 ± 2.29
Caffeine (N=22, 21, 21, 18)5.61 ± 1.875.71 ± 2.016.17 ± 2.296.03 ± 2.13
SecondaryApparent Total Body Clearance (CLT/F) of the Inje Cocktail Components (Midazolam, Losartan, Omeprazole, Dextromethorphan and Caffeine) With and Without Coadministration of Belatacept - PK Evaluable Population

Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of dextromethorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection. CLT/F was measured as liters/hour (L/h)

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Geometric mean · L/h
Apparent Total Body Clearance (CLT/F) of the Inje Cocktail Components (Midazolam, Losartan, Omeprazole, Dextromethorphan and Caffeine) With and Without Coadministration of Belatacept - PK Evaluable Population
L/hDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
Midazolam (N=22, 21, 21, 20)73.8 ± 4971.3 ± 4877.3 ± 5071.4 ± 51
Losartan (N=22, 21, 21, 20)148 ± 37146 ± 36146 ± 34151 ± 44
Omeprazole (N=22, 19, 21, 18)29.2 ± 6623.7 ± 7224.7 ± 7925.3 ± 69
Dextromethorphan (N=18,17,18,18)3916 ± 854247 ± 844264 ± 1263968 ± 107
Caffeine (N=22, 21, 21, 18)4.99 ± 345.30 ± 324.97 ± 364.83 ± 36
SecondaryCmax of Inje Cocktail Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without Coadministration of Belatacept - PK Evaluable Population

Samples for assessment of plasma concentrations of Inje cocktail component metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail component metabolites were each measured using HPLC with MS/MS detection. Cmax was measured in ng/mL.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Geometric mean · ng/mL
Cmax of Inje Cocktail Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without Coadministration of Belatacept - PK Evaluable Population
ng/mLDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
1'-Hydroxy-Midazolam (N=22, 21, 21, 20)11.1 ± 4011.9 ± 4011.4 ± 3812.3 ± 36
E-3174 (N=22, 21, 21, 20)262 ± 37276 ± 33300 ± 33291 ± 41
5-Hydroxyomeprazole (N=22, 21, 21, 20)335 ± 41360 ± 40332 ± 38337 ± 38
Dextrorphan (N=21,20,20,19)342 ± 30324 ± 32312 ± 31331 ± 35
Paraxanthine (N=17,19,18,18)1291 ± 151367 ± 121320 ± 131358 ± 15
SecondaryAUC(0-T) of Inje Cocktail Component Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without Coadministration of Belatacept - PK Evaluable Population

Area under the plasma concentration-time curve from zero to the last time of the last quantifiable concentration \[AUC(0-T)\] was measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Geometric mean · ng*h/mL
AUC(0-T) of Inje Cocktail Component Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without Coadministration of Belatacept - PK Evaluable Population
ng*h/mLDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
1'-hydroxy-midazolam (N=22, 21, 21, 20)28.9 ± 3931.8 ± 3032.5 ± 3233.6 ± 27
E-3174 (N= 22,21,21,20)1995 ± 321999 ± 292089 ± 302072 ± 37
5-hydroxyomeprazole (N=22,21,21,20)997 ± 36967 ± 33929 ± 35995 ± 35
dextrorphan (N=21,20,20,19)1636 ± 271570 ± 261519 ± 271644 ± 26
paraxanthine (N=17,19,18,18)20592 ± 1521077 ± 1620680 ± 1821353 ± 20
SecondaryAUC(INF) of Inje Cocktail Component Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without Coadministration of Belatacept - PK Evaluable Population

Area under the plasma concentration-time curve from time zero extrapolated to infinite time \[AUC(INF)\] was measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Geometric mean · ng*h/mL
AUC(INF) of Inje Cocktail Component Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without Coadministration of Belatacept - PK Evaluable Population
ng*h/mLDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
1'-hydroxy-midazolam (N=22,21,20,20)30.5 ± 3833.8 ± 3232.9 ± 2735.1 ± 27
E-3174 (N=22,20,21,20)2103 ± 322060 ± 292187 ± 312182 ± 38
5-hydroxyomeprazole (N=22,20,21,171010 ± 36990 ± 34938 ± 351063 ± 32
dextrorphan (N=21,20,20,19)1679 ± 251610 ± 251562 ± 261682 ± 25
paraxanthine (N=7,8,6,6)22401 ± 1822905 ± 2422063 ± 1221874 ± 20
SecondaryTmax of Inje Cocktail Component Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without the Coadministration of Belatacept - PK Evaluable Population

Samples for assessment of plasma concentrations of Inje cocktail components metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection. Time of maximum observed plasma concentration (Tmax) was measured in hours (h).

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Median · h
Tmax of Inje Cocktail Component Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without the Coadministration of Belatacept - PK Evaluable Population
hDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
1'-Hydroxy-Midazolam (N=22,21,21,20)1.00 (0.50 to 1.50)1.00 (0.50 to 2.00)1.00 (0.50 to 1.50)1.00 (0.50 to 1.50)
E-3174 (N=22, 21, 21, 20)4.00 (3.00 to 5.03)4.00 (2.00 to 8.00)4.00 (3.00 to 5.15)4.00 (3.00 to 6.02)
5-Hydroxyomeprazole (N=22,21,21,20)2.00 (1.50 to 5.00)3.00 (1.00 to 8.05)3.00 (1.00 to 5.00)2.53 (1.00 to 12.00)
Dextrorphan (N=21,20,20,19)2.00 (1.50 to 4.00)2.00 (1.50 to 4.00)2.00 (1.50 to 3.00)2.00 (1.50 to 4.00)
Paraxanthine (N=17, 19, 18, 18)8.00 (3.00 to 12.02)8.00 (5.00 to 12.00)8.00 (4.0 to 12.00)8.00 (4.00 to 12.00)
SecondaryT-HALF of Inje Cocktail Component Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without the Coadministration of Belatacept - PK Evaluable Population

Plasma half-life (T-HALF) was measured in hours (h). Samples for assessment of plasma concentrations of Inje cocktail components metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Mean · h
T-HALF of Inje Cocktail Component Metabolites (1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine) With and Without the Coadministration of Belatacept - PK Evaluable Population
hDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
1'-Hydroxy-Midazolam (N=22,21,20,20)5.29 ± 2.986.35 ± 3.605.61 ± 3.475.31 ± 2.65
E-3174 (N=22, 20, 21, 20)4.86 ± 0.7494.57 ± 0.7574.75 ± 0.7574.88 ± 0.690
5-Hydroxyomeprazole (N=22,20,21,17)1.43 ± 0.3081.55 ± 0.3971.52 ± 0.3711.54 ± 0.624
Dextrorphan (N=21,20,20,19)4.26 ± 1.604.36 ± 1.464.23 ± 1.134.08 ± 0.999
Paraxanthine (N=7,8,6,6)7.33 ± 1.916.86 ± 1.717.33 ± 1.557.44 ± 2.67
SecondaryRatio of Paraxanthine AUC(0-T) to Caffeine AUC(0-T) and Paraxanthine AUC (INF) to Caffeine AUC (INF), Corrected for Molecular Weight [MR_AUC(0-T) and MR_AUC (INF)] With and Without Coadministration of Belatacept - PK Evaluable Population

Metabolite (paraxanthine) to parent (caffeine) ratio was corrected for molecular weight. AUC (0-T) and AUC (INF) measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Geometric mean · ratio
Ratio of Paraxanthine AUC(0-T) to Caffeine AUC(0-T) and Paraxanthine AUC (INF) to Caffeine AUC (INF), Corrected for Molecular Weight [MR_AUC(0-T) and MR_AUC (INF)] With and Without Coadministration of Belatacept - PK Evaluable Population
ratioDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
MR_AUC(0-T) ratio; N=17,19,18,180.627 ± 240.677 ± 170.635 ± 200.603 ± 21
MR_AUC(INF) ratio; N=7, 8, 6, 60.827 ± 150.827 ± 80.799 ± 140.781 ± 12
SecondaryRatio of Paraxanthine (Cmax) to Caffeine (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population

Metabolite (paraxanthine) to parent (caffeine) ratio was corrected for molecular weight. Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components and their metabolites were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Geometric mean · ratio
Ratio of Paraxanthine (Cmax) to Caffeine (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population
ratioDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
Ratio of Paraxanthine (Cmax) to Caffeine (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population0.303 ± 220.337 ± 150.333 ± 230.323 ± 20
SecondaryRatio of E-3174 AUC(0-T) to Losartan AUC(0-T) and E3174 AUC (INF) to Losartan AUC (INF) Corrected for Molecular Weight [MR_AUC(0-T), MR_AUC(INF)] With and Without Coadministration of Belatacept - PK Evaluable Population

Metabolite (E-3174) to parent (losartan) ratio was corrected for molecular weight. AUC (0-T) and AUC (INF) measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Geometric mean · ratio
Ratio of E-3174 AUC(0-T) to Losartan AUC(0-T) and E3174 AUC (INF) to Losartan AUC (INF) Corrected for Molecular Weight [MR_AUC(0-T), MR_AUC(INF)] With and Without Coadministration of Belatacept - PK Evaluable Population
ratioDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
MR_AUC (0-T) ratio; N=22,21,21,205.81 ± 325.75 ± 335.99 ± 336.17 ± 33
MR_AUC (INF) ratio; N=22,20,21,206.02 ± 305.99 ± 326.16 ± 326.37 ± 31
SecondaryRatio of E-3174 (Cmax) to Losartan (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population

Metabolite (E-3174) to parent (losartan) ratio was corrected for molecular weight. Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Geometric mean · ratio
Ratio of E-3174 (Cmax) to Losartan (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population
ratioDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
Ratio of E-3174 (Cmax) to Losartan (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population2.31 ± 392.24 ± 452.26 ± 432.26 ± 45
SecondaryRatio of 5-Hydroxyomeprazole AUC(0-T) to Omeprazole AUC(0-T) and 5-Hydroxyomeprazole AUC(INF) to Omeprazole AUC(INF) , Corrected for Molecular Weight [MR_AUC(0-T), MR_AUC(INF)] With and Without Coadministration of Belatacept - PK Evaluable Population

Metabolite (5-Hydroxyomeprazole) to parent (omeprazole) ratio was corrected for molecular weight. AUC (0-T) and AUC (INF) measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Geometric mean · ratio
Ratio of 5-Hydroxyomeprazole AUC(0-T) to Omeprazole AUC(0-T) and 5-Hydroxyomeprazole AUC(INF) to Omeprazole AUC(INF) , Corrected for Molecular Weight [MR_AUC(0-T), MR_AUC(INF)] With and Without Coadministration of Belatacept - PK Evaluable Population
ratioDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
MR_AUC (0-T) ratio; N=22,21,21,200.700 ± 570.609 ± 660.551 ± 700.610 ± 66
MR_AUC (INF) ratio; N=22,19,21,170.705 ± 560.558 ± 610.553 ± 690.679 ± 62
SecondaryRatio of 5-Hydroxyomeprazole (Cmax) to Omeprazole (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population

Metabolite (5-hydroxyomeprazole) to parent (omeprazole) ratio was corrected for molecular weight. Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Geometric mean · ratio
Ratio of 5-Hydroxyomeprazole (Cmax) to Omeprazole (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population
ratioDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
Ratio of 5-Hydroxyomeprazole (Cmax) to Omeprazole (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population0.548 ± 540.471 ± 600.424 ± 650.478 ± 59
SecondaryRatio of 5-Dextrorphan AUC(0-T) to Dextromethorphan AUC(0-T) and 5-Dextrorphan AUC(INF) to Dextromethorphan AUC(INF), Corrected for Molecular Weight [MR_AUC(0-T), MR_AUC (INF)] With and Without Coadministration of Belatacept - PK Evaluable Population

Metabolite (5-dextrorphan ) to parent (dextromethorphan) ratio was corrected for molecular weight. AUC (0-T) and AUC (INF) measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Geometric mean · ratio
Ratio of 5-Dextrorphan AUC(0-T) to Dextromethorphan AUC(0-T) and 5-Dextrorphan AUC(INF) to Dextromethorphan AUC(INF), Corrected for Molecular Weight [MR_AUC(0-T), MR_AUC (INF)] With and Without Coadministration of Belatacept - PK Evaluable Population
ratioDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
MR_AUC (0-T) ratio; N=21,20,20,19201 ± 103200 ± 94177 ± 124193 ± 99
MR_AUC (INF) ratio; N=18,17,18,15173 ± 95177 ± 90170 ± 122173 ± 102
SecondaryRatio of 5-Dextrorphan (Cmax) to Dextromethorphan (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population

Metabolite (5-dextrorphan) to parent (dextromethorphan) ratio was corrected for molecular weight. Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. The poor metabolizer of CYP2D6 was excluded from summary of Dextrorphan parameters. Inje cocktail components were each measured using HPLC with MS/MS detection.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Geometric mean · ratio
Ratio of 5-Dextrorphan (Cmax) to Dextromethorphan (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population
ratioDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
Ratio of 5-Dextrorphan (Cmax) to Dextromethorphan (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population280 ± 107303 ± 99275 ± 88303 ± 84
SecondaryRatio of 1'-Hydroxy-Midazolam AUC(0-T) to Midazolam AUC(0-T) and 1'-Hydroxy-Midazolam AUC(INF) to Midazolam AUC(INF), Corrected for Molecular Weight [MR_AUC(0-T), MR_AUC (INF)] With and Without Coadministration of Belatacept - PK Evaluable Population

Metabolite (1'-hydroxy-midazolam) to parent (midazolam) ratio was corrected for molecular weight. AUC (0-T) and AUC (INF) measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Geometric mean · ratio
Ratio of 1'-Hydroxy-Midazolam AUC(0-T) to Midazolam AUC(0-T) and 1'-Hydroxy-Midazolam AUC(INF) to Midazolam AUC(INF), Corrected for Molecular Weight [MR_AUC(0-T), MR_AUC (INF)] With and Without Coadministration of Belatacept - PK Evaluable Population
ratioDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
MR_AUC (0-T) ratio; N=22, 21, 21, 200.421 ± 560.447 ± 460.495 ± 550.472 ± 55
MR_(INF) ratio; N=22, 21, 20, 200.428 ± 570.460 ± 470.479 ± 520.478 ± 55
PrimaryAdjusted Geometric Mean Area Under the Concentration Time Curve (AUC) From Zero to Last Concentration (0-T) and AUC Extrapolated to Infinity (INF) of Midazolam With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population

AUC(0-T): area under the plasma concentration-time curve from zero to the last time of the last quantifiable concentration and AUC (INF): AUC from time zero extrapolated to infinite time were measured in ng\*h/mL. Samples for the assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for midazolam with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Midazolam measured using HPLC with MS/MS Detection.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7and 11
Reported as:
Geometric mean · ng*h/mL
Adjusted Geometric Mean Area Under the Concentration Time Curve (AUC) From Zero to Last Concentration (0-T) and AUC Extrapolated to Infinity (INF) of Midazolam With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population
ng*h/mLDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
AUC (0-T);N=22, 21, 21, 20)65.548 (53.271 to 80.655)68.833 (57.008 to 83.111)63.303 (52.240 to 76.707)67.717 (56.128 to 81.697)
AUC (INF);N=22, 21, 21, 20)67.743 (54.839 to 83.683)71.039 (58.555 to 86.186)65.555 (54.019 to 79.554)69.841 (57.771 to 84.433)
Statistical analysis
  • Day 1 Inje Cocktail vs Day 4 Inje Cocktail Plus Belatacept · Adjusted geometric mean ratio: 1.050 · 90% CI 0.976 to 1.130
  • Day 1 Inje Cocktail vs Day 7 Inje Cocktail · Adjusted geometric mean ratio: 0.966 · 90% CI 0.889 to 1.049
  • Day 1 Inje Cocktail vs Day 11 Inje Cocktail · Adjusted geometric mean ratio: 1.033 · 90% CI 0.950 to 1.123
  • Day 1 Inje Cocktail vs Day 4 Inje Cocktail Plus Belatacept · Adjusted geometric mean ratio: 1.049 · 90% CI 0.975 to 1.127
  • Day 1 Inje Cocktail vs Day 7 Inje Cocktail · Adjusted geometric mean ratio: 0.968 · 90% CI 0.892 to 1.049
  • Day 1 Inje Cocktail vs Day 11 Inje Cocktail · Adjusted geometric mean ratio: 1.031 · 90% CI 0.948 to 1.121
PrimaryAdjusted Geometric Mean Cmax of Losartan With and Without the Coadministration of Belatacept - PK Evaluable Population

Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for losartan with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Inje cocktail components (losartan) measured using HPLC with MS/MS Detection.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Geometric mean · ng/mL
Adjusted Geometric Mean Cmax of Losartan With and Without the Coadministration of Belatacept - PK Evaluable Population
ng/mLDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
Adjusted Geometric Mean Cmax of Losartan With and Without the Coadministration of Belatacept - PK Evaluable Population119.789 (89.629 to 134.485)118.663 (97.209 to 144.850)127.184 (105.467 to 153.373)126.461 (101.676 to 157.288)
Statistical analysis
  • Day 1 Inje Cocktail vs Day 4 Inje Cocktail Plus Belatacept · Adjusted geometric mean ratio: 0.991 · 90% CI 0.898 to 1.093
  • Day 1 Inje Cocktail vs Day 7 Inje Cocktail · Adjusted geometric mean ratio: 0.911 · 90% CI 0.830 to 1.000
  • Day 1 Inje Cocktail vs Day 11 Inje Cocktail · Adjusted geometric mean ratio: 0.994 · 90% CI 0.885 to 1.116
PrimaryAdjusted Geometric Mean AUC (0-T) and AUC (INF) of Losartan With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population

AUC (0-T): area under the concentration curve from time 0 to the time of the last quantifiable concentration and AUC (INF) extrapolated to infinity were measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for losartan with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Inje cocktail components (losartan) measured using HPLC with MS/MS Detection.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Geometric mean · ng*h/mL
Adjusted Geometric Mean AUC (0-T) and AUC (INF) of Losartan With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population
ng*h/mLDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
AUC (0-T) N=22, 21, 21, 20)332.191 (283.753 to 388.898)336.531 (291.278 to 388.815)337.487 (295.482 to 385.462)332.400 (280.799 to 393.484)
AUC (INF) N=22, 21, 21, 20)338.033 (289.143 to 395.189)341.644 (296.237 to 394.012)343.508 (301.494 to 391.378)338.646 (286.824 to 399.831)
Statistical analysis
  • Day 1 Inje Cocktail vs Day 4 Inje Cocktail Plus Belatacept · Adjusted geometric mean ratio: 1.013 · 90% CI 0.944 to 1.088
  • Day 1 Inje Cocktail vs Day 7 Inje Cocktail · Adjusted geometric mean ratio: 1.016 · 90% CI 0.936 to 1.103
  • Day 1 Inje Cocktail vs Day 11 Inje Cocktail · Adjusted geometric mean ratio: 1.001 · 90% CI 0.893 to 1.121
  • Day 1 Inje Cocktail vs Day 4 Inje Cocktail Plus Belatacept · Adjusted geometric mean ratio: 1.011 · 90% CI 0.942 to 1.085
  • Day 1 Inje Cocktail vs Day 7 Inje Cocktail · Adjusted geometric mean ratio: 1.016 · 90% CI 0.938 to 1.101
  • Day 1 Inje Cocktail vs Day 11 Inje Cocktail · Adjusted geometric mean ratio: 1.002 · 90% CI 0.896 to 1.121
PrimaryAdjusted Geometric Mean Cmax of Omeprazole With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population

Cmax: Maximum observed plasma concentration was measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for omeprazole with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Inje cocktail components (omeprazole) measured using HPLC with MS/MS Detection.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Geometric mean · ng/mL
Adjusted Geometric Mean Cmax of Omeprazole With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population
ng/mLDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
Adjusted Geometric Mean Cmax of Omeprazole With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population583.047 (473.091 to 718.560)734.776 (587.280 to 919.316)753.126 (597.946 to 948.579)686.929 (555.590 to 849.315)
Statistical analysis
  • Day 1 Inje Cocktail vs Day 4 Inje Cocktail Plus Belatacept · Adjusted geometric mean ratio: 1.260 · 90% CI 1.118 to 1.421
  • Day 1 Inje Cocktail vs Day 7 Inje Cocktail · Adjusted geometric mean ratio: 1.292 · 90% CI 1.090 to 1.531
  • Day 1 Inje Cocktail vs Day 11 Inje Cocktail · Adjusted geometric mean ratio: 1.178 · 90% CI 0.971 to 1.429
PrimaryAdjusted Geometric Mean AUC (0-T) and AUC (INF) of Omeprazole With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population

AUC(0-T): Area under the plasma concentration-time curve from time zero zero to the time of the last quantifiable concentration and AUC (INF): AUC extrapolated to infinity were measured in ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for omeprazole with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. Inje cocktail components (omeprazole) measured using HPLC with MS/MS Detection.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Geometric mean · ng*h/mL
Adjusted Geometric Mean AUC (0-T) and AUC (INF) of Omeprazole With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population
ng*h/mLDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
AUC (0-T); (N= 22, 21, 21, 20)1361.024 (1066.457 to 1736.953)1577.017 (1200.238 to 2072.075)1671.173 (1278.936 to 2183.704)1653.491 (1264.315 to 2162.463)
AUC (INF); (N= 22, 19, 21, 18)1368.593 (1072.836 to 1745.885)1632.455 (1251.956 to 2128.597)1679.693 (1286.299 to 2193.400)1779.717 (1380.250 to 2294.798)
Statistical analysis
  • Day 1 Inje Cocktail vs Day 4 Inje Cocktail Plus Belatacept · Adjusted geometric mean ratio: 1.159 · 90% CI 1.056 to 1.272
  • Day 1 Inje Cocktail vs Day 7 Inje Cocktail · Adjusted geometric mean ratio: 1.228 · 90% CI 1.092 to 1.381
  • Day 1 Inje Cocktail vs Day 11 Inje Cocktail · Adjusted geometric mean ratio: 1.215 · 90% CI 1.047 to 1.410
  • Day 1 Inje Cocktail vs Day 4 Inje Cocktail Plus Belatacept · Adjusted geometric mean ratio: 1.193 · 90% CI 1.091 to 1.304
  • Day 1 Inje Cocktail vs Day 7 Inje Cocktail · Adjusted geometric mean ratio: 1.227 · 90% CI 1.093 to 1.379
  • Day 1 Inje Cocktail vs Day 11 Inje Cocktail · Adjusted geometric mean ratio: 1.300 · 90% CI 1.141 to 1.482
PrimaryAdjusted Geometric Mean Cmax of Dextromethorphan With and Without the Coadministration of Belatacept - PK Evaluable Population

Cmax was measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for dextromethorphan with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. The poor metabolizer of CYP2D6 was excluded from the statistical analysis. Inje cocktail components (dextromethorphan) measured using HPLC with MS/MS Detection.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Geometric mean · ng/mL
Adjusted Geometric Mean Cmax of Dextromethorphan With and Without the Coadministration of Belatacept - PK Evaluable Population
ng/mLDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
Adjusted Geometric Mean Cmax of Dextromethorphan With and Without the Coadministration of Belatacept - PK Evaluable Population0.927 (0.566 to 1.518)0.800 (0.512 to 1.250)0.855 (0.553 to 1.320)0.794 (0.490 to 1.286)
Statistical analysis
  • Day 1 Inje Cocktail vs Day 4 Inje Cocktail Plus Belatacept · Adjusted geometric mean ratio: 0.863 · 90% CI 0.746 to 0.997
  • Day 1 Inje Cocktail vs Day 7 Inje Cocktail · Adjusted geometric mean ratio: 0.922 · 90% CI 0.793 to 1.071
  • Day 1 Inje Cocktail vs Day 11 Inje Cocktail · Adjusted geometric mean ratio: 0.856 · 90% CI 0.709 to 1.034
PrimaryAdjusted Geometric Mean AUC (0-T) and AUC (INF) of Dextromethorphan With and Without the Coadministration of Belatacept - PK Evaluable Population

AUC(0-T): area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration and AUC (INF): AUC extrapolated to infinity, were measured as ng\*h/mL. Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) and their metabolites (1'-hydroxy-midazolam, E-3174, 5-hydroxyomeprazole, dextrorphan, and paraxanthine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Adjusted geometric mean for dextromethorphan with and without belatacept, along with adjusted geometric mean ratios for Days 4, 7, and 11 versus Day 1, respectively, are presented. The poor metabolizer of CYP2D6 was excluded from the statistical analysis. Inje cocktail components (dextromethorphan) measured using HPLC with MS/MS Detection.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Geometric mean · ng*h/mL
Adjusted Geometric Mean AUC (0-T) and AUC (INF) of Dextromethorphan With and Without the Coadministration of Belatacept - PK Evaluable Population
ng*h/mLDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
AUC (0-T); N= 21, 19, 19, 196.176 (3.466 to 11.005)5.651 (3.305 to 9.661)6.195 (3.705 to 10.358)5.949 (3.465 to 10.215)
AUC (INF); N= 18, 17, 18, 156.220 (3.743 to 10.337)5.455 (3.372 to 8.825)6.412 (4.200 to 9.790)6.359 (1.143 to 9.760)
Statistical analysis
  • Day 1 Inje Cocktail vs Day 4 Inje Cocktail Plus Belatacept · Adjusted geometric mean ratio: 0.915 · 90% CI 0.817 to 1.024
  • Day 1 Inje Cocktail vs Day 7 Inje Cocktail · Adjusted geometric mean ratio: 1.003 · 90% CI 0.856 to 1.175
  • Day 1 Inje Cocktail vs Day 11 Inje Cocktail · Adjusted geometric mean ratio: 0.963 · 90% CI 0.821 to 1.130
  • Day 1 Inje Cocktail vs Day 4 Inje Cocktail Plus Belatacept · Adjusted geometric mean ratio: 0.877 · 90% CI 0.783 to 0.982
  • Day 1 Inje Cocktail vs Day 7 Inje Cocktail · Adjusted geometric mean ratio: 1.031 · 90% CI 0.885 to 1.200
  • Day 1 Inje Cocktail vs Day 11 Inje Cocktail · Adjusted geometric mean ratio: 1.022 · 90% CI 0.839 to 1.245
PrimaryAdjusted Geometric Mean Cmax of Caffeine With and Without the Coadministration of Belatacept - PK Evaluable Population

Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection. Cmax was measured in ng/mL.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Geometric mean · ng/mL
Adjusted Geometric Mean Cmax of Caffeine With and Without the Coadministration of Belatacept - PK Evaluable Population
ng/mLDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
Adjusted Geometric Mean Cmax of Caffeine With and Without the Coadministration of Belatacept - PK Evaluable Population4696.505 (4252.803 to 5186.499)4450.019 (4172.484 to 4746.014)4332.326 (3993.257 to 4700.186)4479.687 (4141.210 to 4845.830)
Statistical analysis
  • Day 1 Inje Cocktail vs Day 4 Inje Cocktail Plus Belatacept · Adjusted geometric mean ratio: 0.948 · 90% CI 0.880 to 1.021
  • Day 1 Inje Cocktail vs Day 7 Inje Cocktail · Adjusted geometric mean ratio: 0.922 · 90% CI 0.857 to 0.993
  • Day 1 Inje Cocktail vs Day 11 Inje Cocktail · Adjusted geometric mean ratio: 0.954 · 90% CI 0.885 to 1.028
PrimaryAdjusted Geometric Mean AUC (0-T) and AUC (INF) of Caffeine With and Without the Coadministration of Belatacept - PK Evaluable Population

Samples for assessment of plasma concentrations of Inje cocktail components (midazolam, losartan, omeprazole, dextromethorphan and caffeine) were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection. AUC (0-T) and AUC (INF) were measured as ng\*h/mL.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Geometric mean · ng*h/mL
Adjusted Geometric Mean AUC (0-T) and AUC (INF) of Caffeine With and Without the Coadministration of Belatacept - PK Evaluable Population
ng*h/mLDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
AUC (0-T); N= 22, 21, 21, 1837394.5 (33103.4 to 42241.8)35200.3 (31255.9 to 39642.5)36853.4 (32319.8 to 42022.9)38407.0 (34164.2 to 43176.7)
AUC (INF); N= 22, 21, 21, 1840084.1 (34881.6 to 46062.5)37647.8 (32705.5 to 43336.9)40149.9 (34434.3 to 46814.1)41537.6 (36092.9 to 47803.7)
Statistical analysis
  • Day 1 Inje Cocktail vs Day 4 Inje Cocktail Plus Belatacept · Adjusted geometric mean ratio: 0.941 · 90% CI 0.874 to 1.013
  • Day 1 Inje Cocktail vs Day 7 Inje Cocktail · Adjusted geometric mean ratio: 0.986 · 90% CI 0.902 to 1.076
  • Day 1 Inje Cocktail vs Day 11 Inje Cocktail · Adjusted geometric mean ratio: 1.027 · 90% CI 0.942 to 1.120
  • Day 1 Inje Cocktail vs Day 4 Inje Cocktail Plus Belatacept · Adjusted geometric mean ratio: 0.939 · 90% CI 0.868 to 1.017
  • Day 1 Inje Cocktail vs Day 7 Inje Cocktail · Adjusted geometric mean ratio: 1.002 · 90% CI 0.914 to 1.098
  • Day 1 Inje Cocktail vs Day 11 Inje Cocktail · Adjusted geometric mean ratio: 1.036 · 90% CI 0.940 to 1.142
SecondaryRatio of 1'-Hydroxy-Midazolam (Cmax) to Midazolam (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population

Metabolite (1'-hydroxy-midazolam) to parent (midazolam) ratio was corrected for molecular weight. Cmax measured in ng/mL. Samples for assessment of plasma concentrations of Inje cocktail components and the metabolites of those components were collected at time = 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours relative to the dosing of belatacept on Day 4 and Inje cocktail dosing on Days 1, 4, 7, and 11, respectively. Inje cocktail components were each measured using HPLC with MS/MS detection.

Time frame:
Pre-dose to 24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11
Reported as:
Geometric mean · ratio
Ratio of 1'-Hydroxy-Midazolam (Cmax) to Midazolam (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population
ratioDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
Ratio of 1'-Hydroxy-Midazolam (Cmax) to Midazolam (Cmax), Corrected for Molecular Weight (MR_Cmax) With and Without Coadministration of Belatacept - PK Evaluable Population0.432 ± 450.476 ± 440.497 ± 460.490 ± 46
SecondaryNumber of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and AEs Leading to Discontinuation - All Treated Participants

Adverse events were coded according to the Medical Dictionary for Regulatory Activities (MedDRA), version 15.1. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Events captured from Day 1 (pre-dose) to last day prior to discharge (Day 46 ±2). In the total group, a participant with an AE is only counted once (ie, data reflected in Days 1, 4, 7, and 11 below could be the same participant with an AE on multiple days of the study).

Time frame:
Day 1 to Day of discharge (Day 46±2)
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and AEs Leading to Discontinuation - All Treated Participants
participantsDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje CocktailAll Participants
Adverse Events42115
SAEs00000
Deaths00000
AEs leading to discontinuation00101
SecondaryNumber of Participants With Marked Serum Chemistry Laboratory Abnormalities - All Treated Participants

Samples for laboratory tests were obtained at Screening visit, Day -1 or prior to dosing on Day 1, Days 3, 6, 10, 46, and at early termination, after 10 hours fasting. Upper limits of normal (ULN); Lower limits of normal (LLN); Pre-therapy (Rx); micromoles per liter (µmol/L); millimoles per liter (mmol/L); grams per liter (g/L); Units per liter (U/L); Aspartate Aminotransferase (AST); Blood Urea Nitrogen (BUN) Total Bilirubin: \>1.1\*ULN if Pre-Rx\<= ULN or Pre-Rx is missing, or \>1.2\*Pre-Rx if Pre-Rx \>ULN. AST: \>1.25\*Pre-Rx if Pre-Rx \>ULN or 1.25\*ULN if Pre-Rx \<= ULN or Pre-Rx is missing. BUN: \>1.1\*ULN if Pre-Rx\<= ULN or Pre-Rx is missing, or \>1.2\*Pre-Rx if Pre-Rx \>ULN. Phosphorus: \<0.85\*LLN if Pre-RX \>= LLN or is missing or if Pre-Rx \< LLN. total Protein: \<0.9\*LLN if Pre-Rx\>= LLN or is missing or Pre-Rx \> LLN. Creatine Kinase: \>1.5\*Pre-Rx if Pre-Rx \> ULN or is missing or Pre-Rx is \<= ULN. Lactate Dehydrogenase: \>1.25\*ULN if Pre-Rx \<= ULN or missing, \>1.5\*Pre-Rx if Pre-Rx \> ULN.

Time frame:
Day -1 to Day 46 ±2 days or at early termination
Reported as:
Number · participants
Number of Participants With Marked Serum Chemistry Laboratory Abnormalities - All Treated Participants
participantsInje Cocktail Alone and Inje Cocktail Plus Belatacept
Total bilirubin >1.1*ULN µmol/L (N=22)1
AST >1.25*Pre-Rx U/L (N=22)1
BUN >1.1*ULN mmol/L (N=22)1
Inorganic Phosphorus <0.85*LLN mmol/L (N=22)1
Total Protein <0.9*LLN g/L (N=22)1
Creatine Kinase > 1.5* Pre-Rx U/L (N=22)2
Lactate Dehydrogenase >1.25*ULN U/L (N=22)1
SecondaryNumber of Participants With Marked Hematology and Urinalysis Laboratory Abnormalities - All Treated Participants

Samples for laboratory tests were obtained at Screening visit, Day -1 or prior to dosing on Day 1, Days 3, 6, 10, 46 ±2, and at early termination, after 10 hours fasting. Leukocytes: \*10\^9 cells per liter (c/L) \< 0.85\*Pre-Rx if Pre-Rx \< LLN or \<0.9\*LLN if LLN \<= Pre-Rx or Pre-Rx is missing. Neutrophils (absolute): \*10\^12 c/L \< 0.85\* Pre-Rx if Pre-Rx \< 1.5, \<1.5 if Pre-Rx \>= 1.5, \< 1.5 if Pre-Rx missing. Urine blood from dipstick: \>=2 if Pre-Rx \<1 or was missing or if Pre-Rx \>=1. Urinary microscopic white blood cells (WBC) and red blood cells (RBC) \>= 2 if Pre-Rx \<2 or if Pre-Rx was missing or \>=4 if Pre-Rx \>=2.

Time frame:
Day -1 to Day 46 ±2 days or at early termination
Reported as:
Number · participants
Number of Participants With Marked Hematology and Urinalysis Laboratory Abnormalities - All Treated Participants
participantsInje Cocktail Alone and Inje Cocktail Plus Belatacept
Leukocytes <0.85*Pre-Rx *10^9 c/L (N=22)1
Neutrophils <0.85*Pre-Rx *10^12 c/L (N=22)4
Urine Blood >= 2 (N=22)2
Urinary RBC microscopic >= 2 (N=8)1
Urinary WBC microscopic >= 2 (N=8)1
SecondaryNumber of Participants With Out-of-Range Electrocardiogram Intervals - All Treated Participants

Participants had 12-Lead electrocardiograms (ECGs) performed at Screening Visit, Day 1 prior to dosing, Day 46 ±2, and at early termination. Definition of out-of-range: PR Interval \>210 milliseconds (msec); QRS \> 120 msec, QT \> 500 msec or \> 30 msec change from baseline (Day 1); QT with Fridericia correction (QTcF) \> 450 msec or change from baseline of \> 30 msec to \<= 60 msec or change from baseline \> 60 msec.

Time frame:
Day 1 to Day 46 ±2 days or at early termination
Reported as:
Number · participants
Number of Participants With Out-of-Range Electrocardiogram Intervals - All Treated Participants
participantsInje Cocktail Alone and Inje Cocktail Plus Belatacept
Day 46 (N=18)0
Early Termination (N=2)0
SecondaryMean Change From Baseline in Sitting Systolic and Diastolic Blood Pressure - All Treated Participants

Systolic and Diastolic blood pressures were taken after the participant had been sitting quietly for at least 5 minutes and the pressures were measured in millimeters of mercury (mm Hg). Pressures were obtained at screening visit, Day -1, and at 0 hour (pre-dose), 0.5 hour (post dose), and 2 hours (post dose) on Days 1, 4, 7, 11. Baseline was defined as last non-missing result with a collection date-time less than the date-time of the first active dose of study drug.

Time frame:
Baseline and 0.5 and 2.0 hours Post Dose on Days 1, 4, 7, and 11
Reported as:
Mean · mm Hg
Mean Change From Baseline in Sitting Systolic and Diastolic Blood Pressure - All Treated Participants
mm HgDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
Systolic 0.5 hour post dose (N=22,21,21,20)-0.6 ± 10.150.1 ± 12.81-4.9 ± 9.05-4.7 ± 10.13
Systolic 2.0 hour post dose (N=22,21,21,20)0.2 ± 10.092.0 ± 11.79-2.7 ± 9.85-2.9 ± 11.73
Diastolic 0.5 hour post dose (N=22,21,21,20)-1.7 ± 6.52-0.2 ± 6.03-2.2 ± 7.54-2.2 ± 5.38
Diastolic 2.0 hour post dose (N=22,21,21,20)0.9 ± 4.67-2.0 ± 4.53-3.4 ± 5.22-1.0 ± 5.83
SecondaryMean Change From Baseline in Sitting Heart Rate - All Treated Participants

Heart Rate was taken after the participant had been sitting quietly for at least 5 minutes and the heart rate was measured in beats per minute (bpm). Heart Rates were obtained at screening visit, Day -1, and at 0 hour (pre-dose), 0.5 hour (post dose), and 2 hours (post dose) on Days 1, 4, 7, 11. Baseline was defined as last non-missing result with a collection date-time less than the date-time of the first active dose of study drug.

Time frame:
Baseline and 0.5 and 2.0 hours Post Dose on Days 1, 4, 7, and 11
Reported as:
Mean · bpm
Mean Change From Baseline in Sitting Heart Rate - All Treated Participants
bpmDay 1 Inje CocktailDay 4 Inje Cocktail Plus BelataceptDay 7 Inje CocktailDay 11 Inje Cocktail
Heart Rate 0.5 hour post dose (N=22, 21, 21, 20)-3.3 ± 12.38-4.2 ± 13.15-1.8 ± 12.58-1.6 ± 10.03
Heart Rate 2.0 hour post dose (N=22, 21, 21, 20)-3.5 ± 10.610.2 ± 13.860.5 ± 11.953.1 ± 11.91
SecondaryMean Change From Baseline in Systolic and Diastolic Blood Pressure at Study Discharge (Day 46±2 Days)

Systolic and Diastolic blood pressures were taken after the participant had been sitting quietly for at least 5 minutes and the pressures were measured in millimeters of mercury (mm Hg). Systolic and Diastolic blood pressures were taken on Day 46 (day of discharge from the study). Baseline was defined as last non-missing result with a collection date-time less than the date-time of the first active dose of study drug.

Time frame:
Baseline and Day 46 ±2 days
Reported as:
Mean · mm Hg
Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Study Discharge (Day 46±2 Days)
mm HgPost Treatment
Systolic (N=18)-5.9 ± 11.25
Diastolic (N=18)-5.7 ± 8.87
SecondaryMean Change From Baseline in Heart Rate at Study Discharge (Day 46±2 Days)

Heart Rate was taken after the participant had been sitting quietly for at least 5 minutes and was measured in beats per minute (bpm). Hear rate was taken on Day 46 (day of discharge) during the follow up period. Baseline was defined as last non-missing result with a collection date-time less than the date-time of the first active dose of study drug.

Time frame:
Baseline and Day 46 ±2 days
Reported as:
Mean · bpm
Mean Change From Baseline in Heart Rate at Study Discharge (Day 46±2 Days)
bpmPost Treatment
Mean Change From Baseline in Heart Rate at Study Discharge (Day 46±2 Days)1.0 ± 15.86

Adverse events

Collected over Day 1 to Day of discharge (Day 46 ±2 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inje Cocktail Alone and Inje Cocktail Plus Belatacept—0/22 (0%)3/22 (13.6%)
Most frequent other events
Most frequent other events
EventInje Cocktail Alone and Inje Cocktail Plus Belatacept
HeadacheNervous system disorders3/22

Baseline characteristics

All participants who received study drug.

Age, Continuous
Age, Continuous(years)Inje Cocktail Alone and Inje Cocktail Plus Belatacept
Mean31.5 ± 5.96
Sex: Female, Male
Sex: Female, Male(Participants)Inje Cocktail Alone and Inje Cocktail Plus Belatacept
Female1
Male21
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Inje Cocktail Alone and Inje Cocktail Plus Belatacept
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American7
White15
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Inje Cocktail Alone and Inje Cocktail Plus Belatacept
United States22
Body Mass Index (kg/m^2)
Body Mass Index (kg/m^2)(kg/m^2)Inje Cocktail Alone and Inje Cocktail Plus Belatacept
Mean24.62 ± 2.886
08

Study locations

1 site
  • Healthcare Discoveries, Llc D/B/A Icon Development Solutions
    San Antonio, Texas 78209, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2013
First posted
Jan 11, 2013
Start
Jan 2013
Primary completionActual
Apr 2013
CompletionActual
Apr 2013
Results first posted
Jun 27, 2014
Last update
Jun 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01766050
Responsible party
Sponsor
First posted
Jan 11, 2013
Start date
Jan 2013
Primary completion
Apr 2013
Completion
Apr 2013
Results posted
Jun 27, 2014
Last update
Jun 27, 2014

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Caffeine · Losartan · Omeprazole · Dextromethorphan · Midazolam · Abatacept

Start the discussion